Resource Summary Report

Generated by ASWG on Aug 9, 2026

PE/Cyanine7 anti-human CD2

RRID:AB_2572066
Type: Antibody

Proper Citation

BioLegend Cat# 300222, RRID:AB_2572066

Antibody Information

URL: http://antibodyregistry.org/AB_2572066

Proper Citation: BioLegend Cat# 300222, RRID:AB_2572066

Target Antigen: CD2

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-human CD2

Description: This monoclonal targets CD2

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone RPA-2.10

Antibody ID: AB_2572066

Vendor: BioLegend

Catalog Number: 300222

Alternative Catalog Numbers: 300221

Record Creation Time: 20250820T044629+0000

Record Last Update: 20250820T195344+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human CD2.

No alerts have been found for PE/Cyanine7 anti-human CD2.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Anderko RR, et al. (2026) Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 596.

Demetriou P, et al. (2025) CD2 costimulation strength: A key regulator of T cell function and anti-tumor immunity that is epigenetically regulated. iScience, 28(12), 113977.

Zou Z, et al. (2024) ATF4-SLC7A11-GSH axis mediates the acquisition of immunosuppressive properties by activated CD4+ T cells in low arginine condition. Cell reports, 43(4), 113995.

Sekiya T, et al. (2024) Tonic TCR and IL-1? signaling mediate phenotypic alterations of naive CD4+ T cells. Cell reports, 43(3), 113954.

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. Molecular cancer therapeutics, 23(1), 68.